CLINICAL TRIALS PROFILE FOR CEFEPIME HYDROCHLORIDE

All Clinical Trials for CEFEPIME HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00020865 ↗	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Unknown status	National Cancer Institute (NCI)	Phase 3	2001-09-01	RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00020865 ↗	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Unknown status	Jonsson Comprehensive Cancer Center	Phase 3	2001-09-01	RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00044759 ↗	Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	1969-12-31	To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
NCT00137787 ↗	Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases	Completed	Bayer	Phase 3	2005-04-01	The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
NCT00137787 ↗	Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases	Completed	Center for Supporting Hematology-Oncology Trials	Phase 3	2005-04-01	The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
NCT00358202 ↗	Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia	Completed	Elan Pharmaceuticals	Phase 4	2002-03-01	Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime is a safe, efficacious, and cost-effective alternative to once daily intramuscular ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do not require hospitalization.
NCT00358202 ↗	Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia	Completed	CPL Associates	Phase 4	2002-03-01	Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime is a safe, efficacious, and cost-effective alternative to once daily intramuscular ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do not require hospitalization.

Clinical Trial Conditions for CEFEPIME HYDROCHLORIDE

Condition Name

Condition Name for CEFEPIME HYDROCHLORIDE
Intervention	Trials
Febrile Neutropenia	5
Complicated Urinary Tract Infection	5
Acute Pyelonephritis	5
Healthy Subjects	3

Condition MeSH

Condition MeSH for CEFEPIME HYDROCHLORIDE
Intervention	Trials
Infections	17
Communicable Diseases	15
Infection	14
Urinary Tract Infections	11

Clinical Trial Locations for CEFEPIME HYDROCHLORIDE

Trials by Country

Trials by Country for CEFEPIME HYDROCHLORIDE
Location	Trials
United States	81
Spain	10
Poland	8
India	8
Brazil	6

Trials by US State

Trials by US State for CEFEPIME HYDROCHLORIDE
Location	Trials
Texas	10
California	8
Florida	6
Pennsylvania	5
New York	5

Clinical Trial Progress for CEFEPIME HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for CEFEPIME HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	2
PHASE1	1
Phase 4	14

Clinical Trial Status

Clinical Trial Status for CEFEPIME HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	28
Not yet recruiting	10
Recruiting	8

Clinical Trial Sponsors for CEFEPIME HYDROCHLORIDE

Sponsor Name

Sponsor Name for CEFEPIME HYDROCHLORIDE
Sponsor	Trials
Wockhardt	7
M.D. Anderson Cancer Center	5
Venatorx Pharmaceuticals, Inc.	4

Sponsor Type

Sponsor Type for CEFEPIME HYDROCHLORIDE
Sponsor	Trials
Other	61
Industry	38
NIH	6

Last updated: July 28, 2026

Cefepime Hydrochloride Clinical Trials Update, Market Analysis, and Revenue Projection (2025-2035)

Executive summary

Cefepime hydrochloride demand is driven by inpatient hospital use for complicated infections, with the near-term market outlook shaped by (1) continued formulary adoption of cefepime versus newer cephalosporins and beta-lactam/beta-lactamase inhibitor (BL/BLI) options, (2) stewardship and resistance pressures, and (3) limited substantive “new entrant” clinical programs for cefepime itself because the active ingredient is mature and largely off-patent in major markets. The most commercially relevant “clinical trials” activity tends to focus on additional indications, comparative effectiveness, dosing optimization, and pharmacokinetic/pharmacodynamic (PK/PD) studies rather than new molecular entities. On revenue, global cefepime revenue is expected to track hospital-acquired infection (HAI) incidence and contracting/antimicrobial stewardship trends, with single-digit CAGR in mature markets through the mid-2020s and a more gradual growth profile thereafter, assuming no major regulatory label expansions that rebase utilization.

No complete, credible dataset specific to your request (trial registries, labeling changes by region, and current unit pricing by manufacturer) is provided in the prompt, so a complete market model and trial-by-trial update cannot be produced without inventing facts.